.png?width=500&height=250&name=%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png)
What is the information provision system?
This guide systematically organizes the "practical essentials" of filing, obtaining, and enforcing patents in the United States—including filing strategies, examination, dispute resolution, post-grant proceedings, and international applications—based on primary sources current as of April 2026 (Title 35 U.S.C., 37 C.F.R., MPEP, USPTO guidance, and CAFC case law).From government fees and major case law (Alice, Mayo, Myriad, KSR, Amgen) to PTAB proceedings, border enforcement (ITC), and annuity management, this guide provides a comprehensive overview of U.S. patent practice.
Table of Contents
- Executive Summary
- Basic Structure of the System and Legal Sources
- Comparison of Application Methods (Provisional, Non-Provisional, PCT)
- Standard Workflow and Timeline Management
- Estimated Government Fees (Filing, Examination, and Annuities)
- Patent Requirements (§101, §102, §103, §112)
- Key Case Law and Practical Implications
- Enforcement and Remedies (§271–§287)
- Strategic Use of the ITC (Section 337)
- PTAB and AIA Reviews (IPR/PGR)
- Maintenance, International Applications, and Recent Legislative Developments
- Practice Checklist
1. Executive Summary
U.S. patent practice is a “hybrid” structure centered on Title 35 (35 U.S.C.), with 37 C.F.R. (implementing regulations), the MPEP (Manual of Patent Examining Procedure), case law (Supreme Court and CAFC), and USPTO guidance collectively governing scope of protection, examination, and disputes.
Four Key Points to Understand in U.S. Patent Practice
- Classify application methods (provisional, non-provisional, and PCT) based on the difference between “methods for securing a priority date” and “entry points into U.S. examination”
- While government fees can be objectively determined using the USPTO fee schedule, managing attorney fees within a range based on case complexity and the number of Office Actions is essential
- Examination issues converge into a triangle formed by §101 (subject matter eligibility) × §112 (enability and disclosure requirements) × §103 (non-obviousness). The Mayo/Alice line of cases and Amgen v. Sanofi have tightened the evidentiary requirements for software/AI and biotechnology
- Disputes in federal district courts (infringement litigation), the ITC (import injunctions), and the PTAB (AIA reviews) mutually influence one another. Design an overall strategy starting from claim interpretation under the Phillips standard and the outlook for injunctions and damages (§283–§287)
2. Basic Structure and Legal Sources of the System
Key Legislation and Operational Layers
The "primary law" of the U.S. patent system is 35 U.S.C. (Patent Act), with §101 (patentability), §102 (novelty and prior art), §103 (non-obviousness), and §112 (disclosure requirements) forming its core.Procedural operations are specified in 37 C.F.R. (Regulations) and the MPEP (Manual of Patent Examining Procedure), which examiners and practitioners refer to (e.g., forms and deadlines for claiming priority, IDS, abandonment, and reinstatement).
Role of the USPTO (United States Patent and Trademark Office)
The USPTO is legally designated as the responsible entity for administrative functions such as patent grant and trademark registration, as well as the provision of information. In practice, it establishes the “rules of practice” for the system through the following three functions:
- Ex parte examination of applications by the Examination Division
- Trials and AIA reviews by the Trial Division (PTAB, etc.)
- Publication of fee schedules, the electronic filing platform (Patent Center), and various guidance documents
The Role of Federal Courts and the ITC
| Forum | Jurisdiction and Characteristics | Legal Basis |
|---|---|---|
| Federal District Courts | Exclusive jurisdiction over patent infringement lawsuits (state courts have no jurisdiction) | 28 U.S.C. §1338 |
| CAFC (U.S. Court of Appeals for the Federal Circuit) | Basic Principles of Judicial Review of PTAB Decisions | By design |
| ITC (U.S. International Trade Commission) | A separate forum specializing in injunctions (exclusion orders) in infringement cases involving imported goods | 19 U.S.C. §1337 |
3. Comparison of Filing Methods (Provisional, Non-Provisional, PCT)
The choice of application method is inextricably linked to the timing of publication, the maturity of R&D, funding plans, and data acquisition plans. We will organize this information around the central question: “How do we establish a priority date and proceed to U.S. examination?”
| Item | Provisional Application | Nonprovisional Application | Transition to the U.S. via PCT |
|---|---|---|---|
| Legal Status | May serve as the basis for domestic priority (under the framework of §119) | Main entry point for U.S. examination (directly linked to requirements under §112, etc.) | Initiates the national phase under §371 |
| Estimated Priority Period | Generally, transition to non-provisional status within 12 months | When involving foreign priority (Paris Convention), the treaty standard is 12 months | The deadline for filing in the U.S. is generally 30 months from the priority date |
| Volume of documentation | The quality of the “disclosure supporting future claims” is decisive (no new matters may be added) | Descriptions satisfying §112(a) + claim drafting are mandatory | Consistency between the original text (PCT) and U.S. requirements (English translation, declaration, and fees) |
| Government fees (Large) | $325 | Base $350 + Search, Examination, and Issuance Fees | Base National Phase fee of $350, etc., plus search and examination fees |
| Typical Use Cases | Early priority date, anticipated data additions, investor relations | Early examination and grant of rights; starting point for division and continuation | Parallel filing in multiple countries, buying time, redesign based on international search results |
Application Document Package
Assuming a non-provisional application, the practical document set consists of the following:
| Documents | Practical Considerations |
|---|---|
| Specification | Meeting the disclosure requirements (§112(a)), including written description, enablement, and best mode, is the "most critical risk management point in U.S. practice" |
| Claims | Simultaneously design term definitions, examples, the depth of embodiments, and a “claim hierarchy” to anticipate interpretation and invalidity attacks in subsequent proceedings (Office Action, litigation, PTAB) |
| Oath/Declaration | Framework for inventor signature and oath (Section 115, 37 C.F.R.) |
| ADS (Application Data Sheet) | Submit standardized bibliographic data and priority claims (37 C.F.R. 1.76) |
| Fees | Multi-tiered structure comprising basic, search, examination, issuance, and excess claim fees |
4. Standard Process Flow and Timeline Management
Systematic “milestone events” are defined as: (i) 18-month publication (Section 122, with exceptions), (ii) Office Action response deadline (SSP + extension), (iii) Grant and issuance, and (iv) Maintenance annuities. Regarding Office Action responses, the regulations provide for an extension system (37 C.F.R. 1.136), and the practice is to pay an extension fee if a response cannot be filed early.
PTA (Patent Term Adjustment): If examination delays exceed a certain threshold—such as delays exceeding three years—the patent term may be adjusted (however, delays attributable to the applicant are deducted).
Flow from Filing to Issuance
① Finalize
invention and filing strategy ↓
② Provisional application or non-provisional
application ↓
③ Formal examination and acceptance
of application
↓ ④ Publication after 18 months (in principle)
↓
⑤ Substantive examination (search and Office Action)
↓
⑥ Response to rejection (amendments, written arguments, or appeal to the PTAB)
↓
⑦ Notice of Allowance → Payment of
Issue Fee ↓
⑧ Patent Issuance
↓
⑨ 3.5/7.5/11.5-year Maintenance Fees
invention and filing strategy ↓
② Provisional application or non-provisional
application ↓
③ Formal examination and acceptance
of application
↓ ④ Publication after 18 months (in principle)
↓
⑤ Substantive examination (search and Office Action)
↓
⑥ Response to rejection (amendments, written arguments, or appeal to the PTAB)
↓
⑦ Notice of Allowance → Payment of
Issue Fee ↓
⑧ Patent Issuance
↓
⑨ 3.5/7.5/11.5-year Maintenance Fees
5. Estimated Government Fees (Filing, Examination, Annuities)
Major Costs by Application Type
Assuming a typical utility (non-provisional) application and listing only basic items (excess claim fees, size fees, translations, IDS, RCE, etc. are separate).
| Category | Provisional Application Fee | Non-provisional: Basic filing fee | Search Fee | Examination fee | Publication Fee |
|---|---|---|---|---|---|
| Large | $325 | $350 | $770 | $880 | $1,290 |
| Small | $130 | $140 | $308 | $352 | $516 |
| Micro | $65 | $70 | $154 | $176 | $258 |
Small/Micro Entity Discount: Since there is a statutory basis (e.g., a 60% reduction for small entities), it is safest to treat the determination and maintenance of eligibility (including the impact of licenses, affiliates, and transfers) as a “continuing obligation.”
Maintenance Fees (Annuities) and Costs of Late Payment and Reinstatement
Annuities are legally designed based on the benchmarks of “3 years and 6 months / 7 years and 6 months / 11 years and 6 months,” and feature a three-tier structure consisting of a 6-month grace period, surcharges, and acceptance of late payments (unintentional) under certain conditions.
| Term | Annuities (Large / Small / Micro) | Grace Period Late Payment Surcharge | Estimated Time for Late Payment Acceptance (Petition) After Grace Period |
|---|---|---|---|
| 3.5 years | $2,150 / $860 / $430 | $540 / $216 / $108 | Example: Delay of 2 years or less: $2,260 (Large), etc. |
| 7.5 years | $4,040 / $1,616 / $808 | $540 / $216 / $108 | Same as above |
| 11.5 years | $8,280 / $3,312 / $1,656 | $540 / $216 / $108 | Same as above |
6. Patent Requirements (§101, §102, §103, §112)
| Provisions | Requirements | Practical Points |
|---|---|---|
| §101 | Subject Matter of Patents: Must fall under the categories of process, machine, manufacture, composition of matter, etc. | Abstract concepts, laws of nature, and natural objects are excluded. The Alice/Mayo two-step test is central to examination practice |
| §102 | Novelty: No prior public knowledge, public use, sale, publication, or patenting prior to the effective filing date | Under the AIA, the first-inventor-to-file system applies. A grace period (1 year) is available |
| §103 | Non-obviousness: Differences from prior art must not be obvious to a person skilled in the art | Under KSR, “common sense, motivation, and predictability” are evaluated flexibly |
| §112 | Disclosure Requirements: written description / enablement / best mode / clarity | Since Amgen, the requirement for enablement of functional genera has become stricter |
Double risk: Since §101 and §112 “struggle to fill each other’s gaps,” it is important to note that over-abstracting under §101 may result in a lack of support under §112, and conversely, over-specifying under §112 may cause the claim to fall into the realm of abstract concepts under §101, creating a double risk.
7. Key Precedents and Practical Implications
| Case Law | Key Issues | Implications for Practice |
|---|---|---|
| Alice (2014) |
Abstract Concepts (Software/Business Methods) | Under Mayo’s two-step test, mere implementation of an abstract concept or general computer use is unlikely to constitute an “inventive concept.” The key is to structure claims around the framework of “technical problem → technical means → technical effect.” |
| Mayo (2012) |
Natural Laws and Diagnosis/Treatment Correlation | Merely stating a natural law plus “apply it” is insufficient; limitation to a specific inventive application is required. In biotechnology and diagnostics, it is crucial to design claims that link to specific procedures, processes, or measurement systems |
| Myriad (2013) |
Products of Nature and cDNA | The mere isolation of naturally occurring DNA tends to negate patent eligibility. cDNA may be treated as distinct from “the natural product itself.” It combines artificial construction (modification, sequence design, conferral of function, and limitation of use) with the requirement of non-obviousness under §112 |
| KSR (2007) |
Framework for determining obviousness | Rejects rigid adherence to the formal "TSM" framework; instead, flexibly evaluates a person of the art’s common sense, design motivation, and the predictability of combinations. Designs that demonstrate "unexpected results," "teaching away," and "inhibited combinations" through evidence are crucial |
| Amgen v. Sanofi (2023) |
Enablement (Functional Genus) | Requires disclosure sufficient for a person skilled in the art to practice the “entire scope of the claims,” taking a strict stance on genus claims broadly defined by function. Strategies involving thick data and claim division are increasing, with a focus on the number of representative examples, structural diversity, and reliance on screening. |
Positioning of Administrative Guidance (Section 101, AI-focused)
- 2019 Revised Patent Subject Matter Eligibility Guidance: Explicitly outlines the categorization of abstract concepts (mathematical concepts, organization of human activities, mental processes) and the evaluation of “practical application”
- 2024 SME Guidance Update (Including AI): Published in the Official Gazette to assist with §101 determinations for AI-related inventions
- AI Inventor Guidance (2024 → 2025 Revision): Emphasizes the distinction that AI is a tool and the inventor is a natural person
8. Enforcement and Remedies (§271–§287)
Types of Infringement (§271)
The core of infringement is unauthorized practice (manufacturing, use, offer for sale, sale, or import) (§271(a)), with derivative forms such as inducement to infringe (§271(b)). In litigation, the following three elements are constructed in parallel:
- Argument of claim satisfaction using a claim chart
- Prior art and invalidity defenses (§102, §103, §112, §101, etc.)
- Requirements for injunctive relief and damages
Typical Process in Federal District Court Litigation
Filing → Answer and Defenses → Discovery → Claim Interpretation (Markman) → Summary Judgment → Trial → Appeal (CAFC)
Phillips Standard for Claim Interpretation: The CAFC has established a framework for interpreting claims that starts with the claim language and places significant weight on extrinsic evidence such as the specification and examination history. Rather than creating a “favorable dictionary” for litigation, it is crucial to maintain consistent definitions and design of embodiments from the time of filing.
Types of Relief (§283–§287)
| Provisions | Content | Practical Points |
|---|---|---|
| §283 | Injunction | The court may grant an injunction in accordance with the principles of equity |
| §284 | Damages | The possibility of treble damages is provided for in the statute (the requirements for treble damages are specified in case law) |
| §285 | Attorney’s fees | In exceptional cases, reasonable attorney fees may be awarded to the prevailing party |
| §286 | Statute of Limitations | Limitation on recovery for infringements occurring more than six years prior |
| §287 | Marking and Notice | Inadequate product marking may limit recovery of damages |
Three design points: (1) Establish a marking system for product lines from the outset; (2) Align the design of infringement notices (when, to whom, under which claims, and regarding which embodiments) with litigation, ITC, and PTAB procedures; (3) Do not leave “weaknesses” in claims unaddressed, with an eye toward fee shifting (§285).
9. Strategic Use of the ITC (Section 337)
The ITC can serve as a strategic forum for obtaining remedies such as exclusion orders against imported goods. The legal basis for this is found in 19 U.S.C. §1337 (Section 337).
Strengths of the ITC
- Unlike district courts, proceedings do not focus primarily on damages; however, the immediate effect of import injunctions is a key strength
- It is well-suited for injunction strategies that target upstream supply chain actors (importers, customs brokers)
- Proceedings are faster than in district court (approximately 15–18 months)
10. PTAB and AIA Reviews (IPR/PGR)
The AIA introduced a framework for challenging post-grant claim validity through administrative proceedings from multiple angles, with the PTAB serving as the primary adjudicating body. PTAB decisions (such as IPR/PGR findings of fact and law) are, by design, subject to appeal to the CAFC.
Procedural Comparison
| Procedure | Petitioner | Government Fees (Major) | Main Purpose |
|---|---|---|---|
| IPR (Inter Partes Review) |
Generally a third party (typically the alleged infringer) | Petition (≤20 claims) $23,750 + $28,125 after initiation |
Parallel invalidity challenge in district court, obtaining a stay, bargaining chip |
| PGR (Post-Grant Review) |
Generally initiated by a third party | Petition (≤20 claims) $25,000 + $34,375 after grant |
Early comprehensive invalidity challenge (eligibility requirements and time period differ from IPR) |
| CBM (Historical System) |
Limited scope | Same fee bracket as PGR on the fee schedule | Post-grant challenges in the financial sector, etc. (refer to past cases) |
Budgeting pitfalls: Note that AIA review costs include not only the petition fee but also a separate “post-institution fee.”
Recent Policy Trends (Regarding the PTAB)
- Proposed Rule in October 2025: Proposal includes how to allocate IPR proceedings to “parallel litigation and claims with res judicata or prior adjudication,” as well as requests for petitioners to waive §102/§103 arguments in other proceedings
- MTA (Motion to Amend): Based on the 2019 pilot program, a final rule was published in 2024, specifying the effective date
- FY25 Statistics: Outcome distributions for petitions, patents, and claims were published, including an institution rate (by petition) of 58%
11. Maintenance, International Applications, and Latest Amendment Trends
Maintenance and Deadline Management
Maintenance fees are primarily required for utility patents (and reissued utility patents); the statutory due dates (3 years and 6 months, 7 years and 6 months, 11 years and 6 months), a 6-month grace period, and acceptance of late payments due to unintentional delay are codified.
Regarding abandonment and reinstatement of applications, reinstatement petitions based on 37 C.F.R. § 1.137 (unintentional delay) are central, and the USPTO clearly specifies the required documents (required reply, fee, unintentional delay statement, etc.).Regarding patent terms, §154 establishes the standard term structure and provisions for PTA (patent term adjustment). For pharmaceuticals and similar fields, extensions due to regulatory compliance (PTE) are provided for under §156.
International Applications and Transitions (Paris Convention, PCT, U.S. Priority Claims)
Deadlines for Claiming Priority (Pitfalls): Regarding foreign priority claims, the MPEP generally outlines a deadline framework such as the “4-month/16-month rule” (the later of 4 months from the U.S. filing or 16 months from the foreign filing) and clarifies that these deadlines are non-extendable. Since relying on post-filing remedies (petitions) significantly increases costs and uncertainty, the practice of obtaining and submitting ADS and priority documents at the time of filing should be implemented.
Transitioning from the PCT to the U.S. is generally designed to enter the national phase 30 months from the priority date, and the framework for U.S. procedures is set forth in §371. When asserting rights based on an international application, certified copies and English translations may be required as necessary (§365).
Key Trends Over the Past Decade
| Field | Trends |
|---|---|
| §101 (Software/AI) | Publication of the 2019 PEG in the Official Gazette and subsequent updates. Supplementary guidance on eligibility assessments, including AI, was issued in 2024 |
| AI Inventors | Revised and replacement guidance in 2025 following the 2024 guidance publication. AI is a tool, and inventors are natural persons |
| Biotechnology (§112 Enablement) | Following Amgen v. Sanofi, the standard for determining enablement of functional genus has been tightened. The USPTO has also published an explanatory memorandum on examination practice |
| PTAB Practices | The final MTA rule (2024) and proposed rules regarding IPR system operations (2025) were published in the Federal Register, and system design (discovery, coordination of parallel litigation, and amendment practices) continues to be updated |
| FY25 Statistics | Institution rates and outcome distributions have been published, allowing the "probability of reaching the end of proceedings" to be factored into case evaluations |
12. Practice Checklist
Pre-filing
- Define the "minimum unit" of the invention and prioritize checking for any deficiencies in disclosures (exemplary embodiments, variations, data) that satisfy §112(a)
- For software/AI, to avoid being reduced to mere restatements of abstract concepts, fix technical effects (performance, resources, security, etc.) in the specifications and prepare materials that can explain “practical application” from the perspective of the 2019 PEG and 2024 AI SME updates
- For biotechnology, be mindful of the Myriad/Mayo/Amgen precedents; plan based on the "breadth" of natural products, correlations, and functional genera, assuming substantial supporting data and claim division (multiple applications)
- Finalize the priority strategy (provisional → non-provisional, Paris, PCT) in conjunction with the “publication date,” “funding,” and “data acquisition plan” (prioritizing the 12-month and 30-month statutory deadlines)
Prosecution
- Design the order of arguments and amendments in responses to Office Actions (OA) based on the possibility of extension (37 C.F.R. 1.136) and cost implications—deciding whether to address issues early or defer them to continuation applications
- Based on KSR, prepare an early evidence plan (affidavits, experimental data, expert testimony, etc.) for §103 defenses that goes beyond mere “logic” to include teaching away and unexpected results
- Be mindful of §112 risks (enablement requirements post-Amgen, etc.); when targeting a broad scope, strengthen the number, diversity, and reproducibility of representative examples, and reconstruct the claim hierarchy via divisional applications (§120)
- Regarding formalities, ensure that avoidable costs—such as Docx requirements and non-electronic filing surcharges—are reliably avoided
Post-filing (Enforcement / Post-grant / Maintenance)
- Before the product is released, design a §287 marking strategy (product, packaging, and virtual marking) to control the starting point for damages recovery (notice)
- For infringement claims, develop a plan to prove the facts of who did what and where, in accordance with the types of infringement under §271 (direct, inducement, etc.)
- When involving AIA reviews (IPR/PGR), pre-plan how to maximize value—whether through district court stays, ITC proceedings, or settlement—based on PTAB statistics regarding “reach rates” (especially since petition fees are two-tiered)
- Schedule patent annuities as mandatory events at 3.5, 7.5, and 11.5 years, and formalize procedures for the “last line of defense,” including a 6-month grace period and relief for late payment (unintentional)
- Since procedural deadlines for foreign priority claims (e.g., the 4-month/16-month rules) are strict, and relying on post-filing remedies (petitions) can lead to skyrocketing costs and uncertainty, implement these strategies at the time of filing
Summary
In U.S. patent practice, claim drafting that accounts for the §101–§103–§112 triangle and a specification depth that anticipates the Phillips standard determine success or failure in examination, litigation, and PTAB proceedings.From the interplay between federal district courts, the ITC, and the PTAB, to the requirements for injunctive relief, damages, and marking (Sections 283–287), and even to the management of annuities and priority-based filing deadlines, there are a wide range of issues that Japanese companies must master from both an offensive and defensive perspective.Strategic responses based on the latest developments in the Alice/Mayo/Myriad/KSR/Amgen case law and USPTO guidance are directly linked to maximizing intellectual property value in the U.S. market.
Consultation on U.S. Patent Applications
EVORIX International Patent Office provides comprehensive support for patent applications and enforcement in major countries, including the United States. From strategic planning for provisional applications and PCT filings to responses to Office Actions, PTAB proceedings, and infringement litigation, our experienced patent attorneys—working in collaboration with local agents—are here to assist you.
*This article is intended to provide general information based on Title 35 U.S.C., 37 C.F.R., the MPEP, USPTO publications, CAFC case law, and other materials as of April 2026. We recommend consulting with experts, including U.S. patent attorneys, for specific decisions regarding individual cases.
